News

News about advances made possible through IPIRA's work, such as innovations commercialized, campus partnerships with industry, and companies born out of licensing UC Berkeley intellectual property rights.

All News

May 13, 2025

Federal appeals court sends CRISPR-Cas9 patent case back to patent office for reconsideration

link

March 18, 2024

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Link

November 12, 2022

Intellia Talks 'Functional Cure' for HAE with Interim Data for 2nd CRISPR Candidate

Link

February 28, 2022

Intellia Therapeutics Shows Improved, Sustained Effect from In Vivo CRISPR Treatment

Link

February 16, 2022

Get Me (DNA) Rewrite: Intellia’s First Acquisition Expands CRISPR Toolkit

Link

January 12, 2022

Intellia Adds Cardiomyopathy Patients to Existing Early-stage ATTR Study

Link

November 22, 2021

Intellia Therapeutics Expands Phase 1 Study to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy

Link

October 13, 2021

Intellia Therapeutics Collaborates with SparingVision to Develop Ocular Therapies

Link

October 6, 2021

Intellia Phase 1/2 Clinical Trial Authorized for Hereditary Angioedema Treatment

Link

June 28, 2021

In Major CRISPR Milestone, Intellia Successfully Edits Genes Inside the Body

Link

October 20, 2020

Intellia to Kick-start First Single-course 'Curative' CRISPR Shot, as it Hopes to Beat Rivals Alnylam, Ionis, and Pfizer

Link

March 31, 2020

FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics

Link

May 11, 2016

Intellia Therapeutics Announces Closing of Initial Public Offering

Link